Trilogy International Partners Inc T.TRL.WT.A

Good News!

[Contrarian333]

Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) announced today that NATESTO^® (testosterone nasal gel) is now on formulary and covered nationwide by a leading national pharmacy benefit manager (PBM) in the United States. This PBM contract provides for unrestricted patient access to NATESTO^® across the PBM’s national open formularies and plans that service government clients. Over six million U.S. lives are covered by these prescription plans.

“The addition of NATESTO^® to a large national formulary in the United States will enable our partner Aytu Bioscience to accelerate prescription growth for the brand in our most important market. With the signing of this payer contract, over six million new patients have gained access to NATESTO^®,” said Ed Gudaitis, President and Chief Executive Officer of Acerus Pharmaceuticals. “We congratulate the team at Aytu for achieving this important milestone.”